Document:

Services Agreement

 Exhibit 10.3 
  
 SERVICES AGREEMENT 
  
 This Agreement is entered into as of October 1, 2005 (the “Effective Date”) by and between B.S. Biology Sciences Limited, a
Cyprus corporation (the “Service Provider”) and Phage Biotechnology Corporation, a Delaware corporation (the “Company”). 
  
 RECITALS 
  
 A. The Service Provider, through itself and its subsidiaries and agents, is engaged in and has considerable experience in the business of developing
pharmaceutical drug manufacturing processes and methods. 
  
 B.
The Company has previously developed a proprietary drug manufacturing process for protein drug candidates (the “Phage Manufacturing Process”) and seeks to develop new generations of the Phage Manufacturing Process that will allow the
Company to remain competitive in the field of protein pharmaceutical manufacturing. 
  
 C. The Company and the Service Provider desire to enter into an agreement whereby the Service Provider will develop and furnish pharmaceutical drug manufacturing services to the Company as specifically set forth
below. 
  
 In consideration of the mutual agreements set forth
below, the Service Provider and the Company agree as follows: 
  
 1. Scope of Services. The Company hereby retains Service Provider to perform the following “Services”: 
  
 (a) Process/Method Development Services. Develop a process that will improve the proprietary Phage Manufacturing Process for the
production of protein drug candidates (the “New Process”). The New Process should improve the fermentation yield of these proteins, as well as possible improvements in the downstream processing and purification. 
  
 (b) Optimizing Manufacturing Process Services.
Optimize the manufacturing process of new drug candidates that have been identified by the Company for commercial development. The Service Provider shall perform the initial steps to allow production of these new drug candidates by the Phage
Manufacturing Process, by synthesizing the genes which would express the new protein candidates, as well as obtaining soluble expression of the protein candidates by the Phage process. 
  
 (c) Additional Services. Such other Services that may be agreed to from time to time pursuant to such
protocol as may be approved in writing by the parties as set forth in Schedule l.(c). 
  
 (d) Instructions and Orders. During the provision of the Services, the Company from time to time shall supply the Service Provider
with specific~ writing instructions and/or orders regarding the tasks to be performed by the Service Provider in connection with process/method development, optimizing the manufacturing process and additional services as 

  

 - 1 - 

 
per provisions of Section 1(a), Section 1(b) and Section 1(c) above and the Service Provider shall act in accordance with such instructions
and orders. 
  
 2. Fees; Payment. In consideration of the
Services, the Company shall pay the Service Provider Twelve Thousand Dollars (US$12,000.00) each month for the services rendered pursuant to this agreement and any additional fees as set forth in Schedule 1 .(c). All payments hereunder shall be made
in US dollars and shall be sent via wire transfer. Service Provider will be solely responsible for and pay all sums due to its subsidiaries or any other parties entitled to receive any compensation in connection with the performance of Services set
forth herein. Service Provider acknowledges that the initial payments under this agreement may be made directly to one of its subsidiaries, Phage Biotech, a Ukrainian limited liability company, if required for purposes of compliance with local
government regulation, but otherwise shall be made directly to Service Provider as soon as practicable. The Company and Service Provider shall cooperate on any other such payments. 
  
 3. Term and Termination. This Agreement shall commence on the date hereof and shall remain in effect until terminated
by either party upon 30 days prior written notice. Paragraphs 4, 5, 6 and 7 shall survive the termination of this Agreement. 
  
 4. Service Provider Warranties. The Service Provider represents and warrants to the Company that: (a) all of the Services will be provided in
accordance with the standards of the U.S. Food and Drug Administration and in a competent, professional and timely manner and in cooperation with the Company’s comments and direction; (b) the Service Provider will perform the Services in
accordance with the specifications and protocols set forth in the attached Schedules from time to time; (c) it has the full and exclusive right and power to enter into this Agreement; and (d) the Developments (as hereinafter defined) will
not infringe upon any common law or statutory rights of any party. 
  
 5. Independent Contractor. Nothing herein shall be deemed or construed to create a joint venture, partnership, agency or employee/employer relationship between the parties for any purpose. The relationship of the parties is
that of independent contractor and client, and is governed solely by this Agreement. Neither party is authorized to act as agent for or otherwise on behalf of the other party, and no action by. Neither party shall bind the other party. The Service
Provider will be solely responsible for payment of any and all taxes and insurance for its employees, including workers’ compensation, hereunder. 
  
 6. Ownership Rights. 
  
 (a) The Service Provider hereby agrees that all experimental results and other data, developments, designs, inventions, discoveries,
improvements (whether patentable or not), patentable or copyrightable subject matter and proprietary information (hereinafter “Developments”), and in each case all intellectual property rights pertaining thereto (including, without
limitation, copyright, patent, trademark, trade dress, trade secret, and other proprietary and moral rights), which the Service Provider makes, conceives or reduces to practice, either solely by itself or, as the case may be, through its
subsidiaries and/or agents, in performing the Services for the Company (each a “Development”) shall be owned exclusively by the Company. In accordance with Ukrainian intellectual property law the Service Provider hereby expressly 

  

 - 2 - 

 
confirms and irrevocably agrees that any and all exclusive proprietary rights to the Developments, including without limitation the right to use the
Developments in any manner whatsoever as a copyrighted object or industrial property object, or any other intellectual property object and the right to allow or prohibit the use of the Developments by other persons shall be vested with the Company
in accordance with Article 16 (2) of the Law of Ukraine “On Copyright and Neighbouring Rights” as well as other intellectual property laws of Ukraine. Without limiting the generality of the foregoing, service Provider specifically
acknowledges and agrees that all tangible expressions of the Developments, including, without limitation, all documents, instruments, sketches, drawings, notes, records, plans, specifications, research, scientific experiments, manuals and tapes, and
all reproductions, copies or facsimiles thereof, have been developed, made or invented exclusively for the benefit of and are the sole and exclusive property of the Company, it successors and assigns and constitute “work for hire”
under Section 201 of Title 17 of the United States Code or similar provisions arising under Ukrainian or other non-U.S. law. If for any reason exclusive ownership of all Developments and the Intellectual Property rights pertaining thereto
is not fully and effectively vested in the Company by the preceding terms, the Service Provider hereby assigns to the Company, and will in the future upon the Company’s request confirm in writing such assignment to the Company, all right, title
and interest Service Provider may have in all portions and aspects of such Developments or portions thereof. The Service Provider warrants and covenants that, in connection with performing the Services for the Company, it has entered and/or will
enter into agreements with its employees, independent contractors, its subsidiaries and/or agents ensuring that the Service Provider has the right to assign all Developments to the Company. The Service Provider agrees that it retains no proprietary
interest in any Developments and, without limitation to the foregoing, hereby waives all moral rights held in connection with any Developments. The Service Provider shall provide necessary assistance, and cause its employees, independent
contractors, its subsidiaries and/or agents to provide necessary assistance, to protect, enforce or perfect the Company’s rights and interests in any Developments, including, without limitation, executing and/or obtaining such assignments,
waivers and other documents as the Company may request to give full effect to the provisions of this Section 6. Service Provider irrevocably appoints, and shall require its employees, independent contractors, its subsidiaries and/or agents, to
appoint the Company as attorney-in-fact with full power to execute, acknowledge, deliver and record in the United States Copyright and or Patent Offices or elsewhere any and all such documents Service Provider, it employees and/or independent
contractors fail to execute and deliver. The appointment shall be a power coupled with an interest. The Service Provider agrees that the Service Provider shall not register, file or obtain any patent, copyright or trademark relating to any of the
Developments in its own name or in the name of its employees, independent contractors, its subsidiaries and/or agents involved in performing the Services for the Company, and it shall use its best effort to ensure that its employees, independent
contractors, its subsidiaries and/or agents shall not register, file or obtain any patent, copyright or trademark relating to any of the Developments in their name. 
  
 (b) In accordance with the foregoing, the Service Provider shall require all subsidiaries and/or agents
performing Services for the Company pursuant to this Agreement to acknowledge in writing their agreement to comply with the terms of Paragraph 6(a) that vest ownership of all Developments and the intellectual property rights pertaining thereto with
the Company. A non-limiting example of a writing to accomplish the requirements of this Paragraph 6(b) and of Paragraph 7(b) below is provided in the attached Schedule 6.(b). 
  

 - 3 - 

 7. Confidentiality. 
  
 (a) The Service Provider shall not, at any time from and after the date hereof and throughout perpetuity,
directly or indirectly, disclose, reveal or permit access to all or any portion of the Confidential Information (defined in Paragraph 7(b) below), or any tangible expressions or embodiments thereof (including any facilities, apparatus or equipment
which embody or employ all or any portion of the Confidential Information), to any Person (defined in Paragraph 7(c) below) without the written consent of the Company, except to Persons designated or employed by the Company. In addition, the Service
Provider agrees not to use any Confidential Information for its own benefit, and that rather, such Confidential Information is to be used solely for the purposes set forth in this Agreement. 
  
 (b) The Service Provider shall require all subsidiaries
and/or agents performing Services for the Company pursuant to this Agreement to acknowledge in writing that they may be receiving Confidential Information during the course of their conducting services in accordance with this Agreement, and that
they agree to comply with the terms of Paragraph 7(a) mandating non-disclosure and non-use of such Confidential Information in the same manner as if they were the Service Provider. A non-limiting example of a writing to accomplish the requirements
of this Paragraph 7(b) and of Paragraph 6(b) above is provided in the attached Schedule 6.(b). 
  
 (c) “Confidential Information” means all information of any kind, type or nature (written, stored on magnetic or other
media or oral) which at any time during the engagement of the Service Provider by the Company is, has been or will be compiled, prepared, devised, developed, designed, discovered or otherwise learned of by the Service Provider to the extent that
such information relates to the Company or any of its affiliated entities including, without limitation, all of the Company’s price lists, pricing information, customer lists, customer information, financial information, trade secrets,
formulas, patterns, compilations, research, devices, methods, techniques, processes, confidential trade knowledge, source code and computer programs and information; provided, however, that any such information which is generally known
to the public or which may be obtained by a reasonably diligent person without material cost or effort from trade publications or other readily available and public sources of information shall not be deemed to be Confidential Information, unless
such information was first published in breach or in violation of a confidentiality or similar agreement, including this Agreement. 
  
 (d) “Person” means any individual, corporation, partnership, trust, government or regulatory authority, or other entity.

  
 8. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of California, without regard to conflict of law principles. The Service Provider hereby unconditionally and irrevocably agrees and consents to the exclusive jurisdiction of the federal and
state courts located in Orange County, California, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. 
  

 - 4 - 

 9. Attorney’s Fees. In the event that any dispute between the Service Provider and the
Company should result in litigation, the prevailing party in such dispute shall be entitled to recover from the other party all reasonable fees, costs and expenses, including without limitation, reasonable attorney’s fees and expenses.

  
 10. Waiver/Severability. No waiver of any breach or
default hereunder shall be deemed a waiver of subsequent breach or default of the same, similar or related nature. No waiver shall be binding unless in writing and signed by the person making the waiver. In the event any clause or portion of this
Agreement shall be held invalid by any court, it is understood and agreed that such invalid clause or portion thereof shall have no effect upon the validity of other portions of this Agreement. 
  
 11. Notices. All notices, consents and approvals under this Agreement
shall be given in writing, sent by (i) certified or registered mail, return receipt requested, postage prepaid, (ii) personal delivery, (iii) overnight or other express mail, or (iv) facsimile with a hard copy to follow by any of
the means set forth above, to Company or Service Provider at the respective addresses set forth below in the signature block or such other address as may be designated by written notice to the other parties. 
  
 12. Counterparts. This Agreement may be executed in any number of
counterparts, including counterparts transmitted by facsimile, each of which shall be an original as against any party whose signature appears thereon and all of which together shall constitute one and the same instrument. This Agreement shall
become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as signatories. 
  
 13. Entire Agreement. This Agreement contains the entire agreement of the parties relating to the subject matter
hereof. This Agreement may only be amended in a writing signed by both parties hereto. In the event of a conflict between the terms of the schedules and the terms and conditions set forth in the body of this Agreement, the terms and conditions set
forth in the body of this Agreement shall prevail. 
  
 IN WITNESS
WHEREOF, the Company and the Service Provider have duly executed this agreement as of the date first written above, October 1, 2005 (the “Effective Date”). 
  

									
	 PHAGE BIOTECHNOLOGY CORPORATION,
 a Delaware
corporation
	 	 	 	 B.S. BIOLOGY SCIENCES LIMITED,
 a Cyprus
limited liability company

					
	By	 	/S/    JACK
JACOBS        	 	 	 	By	 	/S/    PETROS
LIVANIOS        
	 Name
	 	Jack Jacobs	 	 	 	 Name
	 	Petros Livanios
	 Title
	 	VP & COO	 	 	 	 Title:
	 	Director
	 Address
	 	 	 	 	 	 Tax ID Number:
	 	 
					
	 Facsimile
	 	 	 	 	 	 Facsimile
	 	 

  

 - 5 - 

  
 SCHEDULE 1.(c)

  
 Work to be Performed:
                                        
             
  
 Due Date:                     
  
 Fee: 
  
 Deliverables:                                    
             
  
 Interval Reporting: 
  
 Estimated
Costs:                                     
  

			
		
	For Service Provider:	 	 
	 	 	 Name:______________________________

	 	 	 Title:_______________________________

	 	 	 Date:_______________________________

		
	For Company:	 	 
	 	 	 Name:______________________________

	 	 	 Title:_______________________________

	 	 	 Date:_______________________________

  

 - 6 - 

 SCHEDULE 6.(b) 
  
 Phage Biotech, a Ukrainian limited liability company (the “Subsidiary/Agent”), has reviewed the Services Agreement between B.S. Biology
Sciences Limited and Phage Biotechnology Corporation that is effective June 1, 2005. The Subsidiary/Agent understands that it is being hired by B.S. Biology Sciences Limited to complete a certain part of the services B.S. Biology Sciences
Limited agreed to perform for Phage Biotechnology Corporation pursuant to that Agreement. In consideration for the payment that Subsidiary/Agent is to receive for conducting these services, Subsidiary/Agent acknowledges the terms of
Paragraphs 6(a) and 7(a) of the Agreement, and agrees to be bound by those terms to the same extent as if B.S. Biology Sciences Limited were performing the services itself Specifically, Subsidiary/Agent acknowledges that Subsidiary/Agent may be
receiving Confidential Information during the course of conducting services in accordance with this Agreement, and that Subsidiary/Agent agrees to comply with the terms of Paragraph 7(a) mandating non-disclosure and non-use of such Confidential
Information in the same manner as if they were B.S. Biology Sciences Limited, and also agrees to comply with the terms of Paragraph 6(a) that vest ownership of all Developments and the intellectual property rights pertaining thereto with Phage
Biotechnology Corporation. 
  

					
	 	 	 	 	Subsidiary Agent
			
	Dated:____________________	 	 	 	/S/
	 	 	 	 	Phage Biotech,
	 	 	 	 	 a Ukrainian limited liability company

  

 - 7 -Master Agreement

 Exhibit 10.4 
  
 MASTER AGREEMENT 
 by and between 
 MPI RESEARCH, INC. 
 (hereinafter referred to as Mfl) 
 Mattawan, Michigan 
 and 
 PHAGE BIOTECHNOLOGY CORPORATION

 (hereinafter referred to as the SPONSOR) 
 Tustin, California 
  
 Notice: This
document contains Company Confidential and/or Proprietary Information belonging to MPI and the Sponsor. None of the information may be copied, transmitted or communicated in whole or in part to any third party without the written consent of the
parties. 
  
 DEFINITIONS 
  

	 	•	 	The Master Agreement outlines the general terms of the contract between MPI and the SPONSOR. 

  

	 	•	 	The Services Agreement details the specific terms for each study of the contract between MPI and the SPONSOR. This includes the billing schedule for the study.

  

	 	•	 	The protocol is a detailed description of die study as required in the applicable Good Laboratory Practices regulations. 

  
 II. WORK TO BE DONE AND COSTS 
  
 MPI agrees to carry out the study(ies) for the SPONSOR according to the
written protocol(s). The protocol(s) are attached as Exhibit A to the Services Agreement Addendum and are incorporated herein by reference. For performing this (these) study(ies), MPI shall receive the sums indicated On the Services Agreement
Addendum for each study performed for the SPONSOR. 
  
 In the
performance of this agreement, MPI shall comply with all applicable U.S. laws, ordinances, rules and regulations, whether federal, state or local. MPI affirms that it is registered with the USDA as a laboratory conducting research on laboratory
animals and that all conditions of animal care and testing will conform to the Animal Welfare Act. MPI is an AAALAC accredited facility and MPI warrants that, to the best of its knowledge, it is currently in compliance with and that it will, to the
best of its ability, remain in compliance with arid fulfill all governmental requirements regarding applicable Good laboratory Practices. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 2 
  
 III. CONFIDENTIALITY 

 
 MPI agrees that it shall not disclose to any third party any information
concerning the study(ies) or any data derived therefrom that it obtains during the course of its performance of this agreement without the prior written consent of the SPONSOR. Appropriately authorized regulatory officials will he provided access to
study information upon request, and MPI will notify the SPONSOR immediately upon the regulatory official’s request. This obligation shall survive the cancellation or the termination of this agreement. MPI agrees to (i) limit access to the
study(ies) and data derived therefrom to its employees, agents and consultants who require access in order to perform the study(ies) in compliance with the Protocol(s) of this agreement, and (ii) to take all reasonable precautions to maintain
the confidentiality of the study(ies) and data derived therefrom, using at least those precautions that MP1 uses to protect its own proprietary material. 
  
 MPI shall not use any samples of test material supplied to MPI by the SPONSOR for any purpose(s) other than this (these) study(ies) and shall not assign
or transfer sanm to any third party without the prior written authorization from the SPONSOR. 
  
 The SPONSOR agrees that it shall not disclose to any third party any information concerning MPI proprietary information that the SPONSOR obtains during the course of this agreement without the prior written consent of
MPI, using at least those precautions that the SPONSOR uses to protect its own proprietary material. 
  
 IV. METHOD OF PAYMENT 
  
 The SPONSOR shall make payment in United States finds upon receipt of an invoice and in accordance with the payment schedule outlined in the applicable Services Agreement Addendum. 
  
 V. MODIFICATION IN SERVICES AGREEMENT(S) AND/OR PROTOCOL(S) 
  
 If, at a future date, changes in the Services Agreement(s) or Protocol(s)
are necessary, such changes will be made through prior written agreement between the SPONSOR and MPI. If changes in Protocol(s) affects the cost of the (these) study(ies), MPI shall submit a revised Services Agreement for approval by the SPONSOR and
make the change after receiving written authorization. On occasion, changes may be made after oral authorization of the SPONSOR, but these must he followed by written authorization of the SPONSOR. MPI shall not subcontract this (these) study(ies) or
any part(s) thereof without the SPONSOR’s prior written approval. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 3 
  
 VI. SANDARDS OF PERFORMANCE

  
 MPI shall exercise reasonable care and a high standard of
professional conduct in the performance of the work under this Master Agreement and each Services Agreement and in the preparation of resulting report(s) in accordance with the Protocol(s). MW shall perform its work in accordance with the Services
Agreements/Protocol(s). In the event of an error or omission in the performance of the work by MPI, the SPONSOR will be notified. if such an error or omission causes the (these) study(ies) results to be invalidated by regulatory authorities, MPIs
sole obligation and liability shall be to repeat the (these) study(ies) or the affected part thereof in accordance with the Protocol(s) at no additional cost to the SPONSOR. In no event shall MPI be liable for any incidental, consequential or
special damages beyond the control of MPI or in excess of the study(ies) price, including but not limited to loss of anticipated income or business disruption, even if MPI has been advised of the possibility of such damages. 
  
 OTHER THAN TILE WARRANTIES EXPRESSLY STATED ABOVE, THERE ARE NO EXPRESSED OR
IMPLIED WARRANTIES RELATED TO ANY OF THE SERVICES COVERED BY THIS MASTER AGREEMENT OR ANY SERVICES AGREEMENT(S), INCLUDING BUT NOT LIMITEI) TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
  
 VII. INDEMNIFICATION 
  
 Each of the parties agrees to indemnify and hold harmless the other patty and its affiliates and their respective employees,
agents, officers, directors and permitted assigns (such party’s “Indemnified Group”) from and against any claims by a third party, and any resulting judgments, expenses (including reasonable attorney’s fees), damages and awards
(collectively, a “Claim”) arising out of or resulting from (i) its negligence or willful misconduct or (ii) a breach of any of its obligations, representations or warranties hereunder, except to the extent that such Claim arises
out of or results from any negligence or willful misconduct of a party seeking to be indemnified and held harmless or the negligence or willful misconduct of a member of such party’s Indemnified Group. A condition of this obligation is that,
whenever an indemnified party has information from which it may reasonably conclude an incident has occurred which could give rise to a Claim, such indemnified party shall promptly give written notice to the indemnifying party of all pertinent data
surrounding such incident and, in the event a Claim is made or suit is brought, all indemnified parties shall assist the indemnifying party and cooperate in the gathering of information with respect to the time, place and circumstances and in
obtaining the names and addresses of any injured parties and available witnesses. No indemnified party shall, except at its own cost, voluntarily make any payment or incur any expenses in connection with any such Claim without the prior written
consent of the indemnifying party. The obligations set forth in this Section shall survive the expiration or termination of this agreement. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 4 
  
 VIII. FORCE MAJEURE

  
 MPI shall exercise every reasonable effort to meet the
agreed upon completion date for the (these) study(ies), MPI shall not be liable for any loss or damage due to delays resulting from any cause(s) beyond its reasonable control such as, but not limited to, changes to any government law or regulation
that occur during the course of a study, acts of God, acts or omission of the SPONSOR, acts of civil or military authority, judicial action, labor disputes, epidemics, explosions,
accidents, quarantine restrictions, failure due to delay in transportation, embargoes, wars, riots, or delays caused by the SPONSOR. In the event of any delay due to such cause or
other difficulties, whether or not similar in nature to any of those enumerated, the delivery dates shall be extended for a period equal to the extent of the delay so incurred. In any ease, MPI shall report in writing the reasons for the delay to
the SPONSOR. 
  
 IX. MONITORING OF STUDY(IES) 
  
 Authorized representatives of the SPONSOR have the right to inspect the
study(ies) animals and/or raw data on the premises of MPI during regular working hours. Advance notice of SPONSOR inspections is appreciated. MPI shall notify the SPONSOR, by facsimile or by telephone, of any changes in the study design from that
specified in the protocol that occur at any time during the (these) study(ies). Changes, which MPI and the SPONSOR mutually agree to be significant, will be detailed in writing and sent to the SPONSOR. 
  
 In the event that the SPONSOR requests copies of the data derived from
SPONSOR studies conducted at MPI, the SPONSOR agrees to pay MPI for the preparation, verification, duplication and handling of such data in accordance with MPI’s established charges for such services at that time. 
  
 In the event that the SPONSOR requests original documents or data from the
study(ies), the SPONSOR agrees to pay MPI for the preparation of such original data and applicable shipping charges in accordance with MPI’s established charges for such services at that time. 
  
 X. EARLY TERMINATION 
  
 The SPONSOR shall have the privilege of curtailing or terminating the Services Agreement(s) or Protocol(s) at any time
without incurring penalty costs by giving MPI 30 days written notice of this intent. Any such notice shall specify the date of curtailment or termination. In the event of such curtailment, MPI and the SPONSOR shall negotiate new charges for the
remaining services and amend in writing the payment schedule of the affected Services Agreement Addendum relating to the curtailed services In the case of early termination of any Services Agreement or Protocol, MPI shall refund the amount overpaid.
Should study costs to termination exceed the SPONSOR’S payments, the SPONSOR will pay the balance to MPI. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 5 
  
 XI: REPORTS 
  
 One bound and one unbound copy of the audited draft and final study(ies)
report(s) in compliance with the Protocol(s) shall be provided to the SPONSOR If additional reports are requested, an additional charge shall be made for their preparation and handling in accordance with MPI’s established charges for such
services at that time, The SPONSOR may request one set of changes to the audited draft report at no additional cost. Additional changes may result in additional charges in accordance with MPI’s established charges for such services at that
time. 
  
 XII: STORAGE OF RAW DATA 
  
 MPI agrees that the raw data and study specimens are the exclusive property
of the SPONSOR, and MPI shall store the data arid study specimens derived pursuant to this Master Agreement for a period of one year following the completion of the study (final report issue date). At the expiration of this time, the SPONSOR shall
be notified as to the disposition of the raw data and/or study Specimens as outlined below. During archival storage, MPI shall ensure that all raw data and study specimens will be readily available for inspection by the SPONSOR or an authorized
agent designated by the SPONSOR. Notwithstanding the foregoing, MPI shall not discard or destroy any raw data, or other materials relating to this (these) study(ies) without giving the SPONSOR written notice of this intention and a reasonable
opportunity to have such raw data or other material relating to these studies shipped to the SPONSOR, or to another facility selected by the SPONSOR, at the SPONSOR’s expense. 
  
 MPI shall not be liable for any loss or damage to the raw data or study specimens resulting from any cause(s) beyond its
reasonable control such as, but not limited to acts of God, acts or omissions of SPONSOR, act of civil or military authority, judicial action, labor disputes, epidemics, explosions, accidents, quarantine restrictions, failure due to delay in
transportation, embargoes, wars, or riots. In the event that the raw data or study specimens are damaged from any cause(s) that MPI could reasonably have foreseen and the raw data or study specimens are needed so that the SPONSOR can respond to
inquiries from regulatory authorities, MPI agrees to repeat, at MPI’s cost, the study or any portion thereof necessary to respond to such inquiries. MPI shall not he liable for any other loss, claim, damage, or expense incurred by the SPONSOR,
including but not limited to loss of anticipated income or business disruption. 
  
 XIII, PATENTS AND INVENTIONS 
  
 MPI
agrees that all reports, conclusions, data and other information obtained or developed through its work on the(se) study(ies) will be the property of SPONSOR and will be made available to the SPONSOR at any time subject to the terms and conditions
of this Agreement. MPI further agrees to communicate to the SPONSOR promptly and without request all information pertinent to the(se) study(ies) as it progresses. MPI agrees to disclose to the SPONSOR any invention, discovery or patentable or

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 6 
  
 unpatentable
improvement conceived or developed in connection with this Agreement by MPI (alone or with others) or by any contractor, but excluding any testing methodology innovation developed by MPI (luring the term of this Agreement. MPI agrees to execute any
assignment or other documents reasonably necessary to convey to the SPONSOR any copyright, title or other interest to such information. MPI will not disclose to any third party any invention, discovery or improvement (except testing methodology
Innovations) developed in connection with this Agreement without SPONSOR’S express written authorization. 
  
 XIV. ADVERTISING 
  
 Under no circumstances, shall the name of MPI or any of its personnel be used for promotional literature or advertising without the prior written approval of MPI. The SPONSOR may use all or any portion of the report(s) or content(s) of the
study(ies) conducted by MPI under this Master Agreement. The SPONSOR may indicate that the study(ies) were conducted by MPI in order to obtain governmental approval or clearance for the commercialization of the test material of the study(ies) and
its preparation(s). 
  
 Under no circumstances may the name of
SPONSOR or any of its personnel and affiliates be used for promotional literature or advertising without the prior written permission and approval of the SPONSOR. 
  
 XV. PUBLICATIONS 
  
 The SPONSOR has the right to the publication of the results of the (these) study(ies) or to a joint publication with MPI. The SPONSOR
may authorize MN to publish the results of this(these) study(ies) independently. 
  
 XVI. REGULATORY REQUIREMENTS 
  
 MPI agrees that
all animals used in any study conducted by MPI under this Master Agreement will be handled, housed and, as appropriate, disposed of in accordance with the current NIH guidelines regarding the care and use of laboratory animals and all applicable
local, state and federal laws, regulations and guidelines. 
  
 It
is agreed that, unless specified to the contrary in a selected Services Agreement, all studies conducted by MPI shall comply with applicable Good Laboratory Practices. MPI will promptly notify the study monitor (identified in the appropriate
Services Agreement) of any unforeseen or unusual incident that may affect the outcome of the study. 
  
 XVII. MISCELLANEOUS 
  
 It
is the intention of’ the patties that no form of legal “agency” relationship be created between the parties and nothing in this Agreement shall be deemed to create in either party the right or authority to incur any obligation on
behalf of the other party or to bind such other party in any way whatsoever except in accordance with the terms of this Agreement. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 7 
  
 Modification of this
Master Agreement or any Services Agreement Addendum shall be binding only if in writing and signed by both parties. 
  
 This agreement and all schedules, attachments and exhibits contain the parties’ entire agreement and understanding, and it supersedes all prior oral
and written agreements and understandings. In the event of a conflict between the Master or Services Agreements and the study Protocol, the Master and Services Agreements shall supersede the Protocol. - 
  
 The laws of the State of Michigan including its choice of law rules shall
govern this Master Agreement and the services to be performed hereunder. 
  
 If any provision of this Master Agreement or any schedules or attachments is held invalid, illegal or unenforceable, all other provisions of this Master Agreement and such schedules and amendments shall remain in
effect. If any provision of this Master Agreement is held to he excessively broad as to duration, geographic scope, activity or subject, it is to be construed by limiting and reducing it, so as to he enforceable to the extent compatible with the
applicable law. 
  
 All written notices from one party to the
other under this Master Agreement are sufficient as sent to the address listed below by certified or registered mail, postage prepaid. Notices to MPI shall be sent to the attention of the President, Chief Operating Officer. Notices are
effective upon receipt. 
  

			
	SPONSOR’S REPRESENTATIVE:	  	Jack Jacobs, Ph.D.
	 	  	Vice President & (chief Scientific Officer)
		
	SPONSOR’S ADDRESS:	  	Phage Biotechnology Corporation
	 	  	14272 Franklin Avenue
	 	  	Suite 110
	 	  	Tustin, CA 92780
		
	MPI’S ADDRESS:	  	MPI Research, Inc.
	 	  	54943 North Main Street
	 	  	Mattawan, MI 49071-9399 USA

  
 This Master Agreement
may be executed in two counterparts each of which shall be deemed an original, but both of which together shall constitute one in the same document. 

 MASTER AGREEMENT 
 Phage Biotechnology Corporation 
 Page 8 
  
 IN WITNESS
WHEREOF, the party’s authorized representative has duly executed this agreement as of the day and year indicated below. 
  

			
	FOR: Phage Biotechnology Corporation
		
	BY:	 	 /s/ Jack Jacobs

	TITLE:	 	VP & COO
		
	DATE:	 	 3/8/04

	
	FOR: MPI Rcsearch, Inc.
		
	BY:	 	 /s/ Andrejs P. Dumpis

	TITLE:	 	Chief Accounting Officer, Treasurer
		
	DATE:	 	 3/10/04

	
	FOR: MPI Research, Inc.
		
	BY:	 	 /s/ William Harrison

	 	 	William Harrison
	TITLE:	 	President and Chief Operating Officer
		
	DATE:	 	 3/10/04

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]